See more here:
Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment
Related Post
- Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025 - March 9th, 2025
- Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion... - March 9th, 2025
- NewGenIvf Provides Update on Proposed Reverse Merger with European Wellness Holdings and Completion of Strategic Acquisition of MicroSort Reproductive... - March 9th, 2025
- Artax Biopharma Presents New Preclinical Data on Nck Modulators at 2025 AAD Annual Meeting - March 9th, 2025
- Virbac : Declaration of the number of shares and voting rights 02/25 - March 9th, 2025
- Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering - March 9th, 2025
- Tsay Keh Dene Nation partners with Tersa Earth to drive sustainable mining solutions - March 9th, 2025
- Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET - March 9th, 2025
- Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - March 9th, 2025
- Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel - March 9th, 2025
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - March 9th, 2025
- Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - March 9th, 2025
- RAPT Therapeutics to Participate in Upcoming Investor Conferences - March 9th, 2025
- Blueberries Medical Announces C$1 Million Non-Brokered Private Placement - March 9th, 2025
- Better Choice Company to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 27th at 4:30 p.m. ET - March 9th, 2025
- Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - March 9th, 2025
- Curia Announces Strategic Refinancing to Support Continued Growth - March 9th, 2025
- Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD - March 9th, 2025
- Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis - March 9th, 2025
- Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD - March 9th, 2025
- Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - March 7th, 2025
- Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences - March 7th, 2025
- aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - March 7th, 2025
- Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - March 7th, 2025
- NextCure Provides Business Update and Reports Full Year 2024 Financial Results - March 7th, 2025
- Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - March 7th, 2025
- Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - March 7th, 2025
- Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - March 7th, 2025
- Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American... - March 7th, 2025
- CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - March 7th, 2025
- Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 - March 7th, 2025
- Raw Garden Introduces Sprout™ Vape, Pioneering Terpene-Safe Plastic for Cannabis Hardware - March 7th, 2025
- Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - March 7th, 2025
- Tarsus to Participate in Upcoming Investor Conference - March 7th, 2025
- Mesoblast Added to S&P/ASX 200 INDEX - March 7th, 2025
- BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025 - March 7th, 2025
- Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston - March 7th, 2025
- Amaran Biotech Signs MOU with Nippon Fine Chemical - March 7th, 2025
- Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older - March 7th, 2025
- argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting - March 7th, 2025
- NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented - March 5th, 2025
- NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising... - March 5th, 2025
- Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - March 5th, 2025
- Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida - March 5th, 2025
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - March 5th, 2025
- Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference - March 5th, 2025
- Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in... - March 5th, 2025
- Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - March 5th, 2025
- Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - March 5th, 2025
- Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis - March 5th, 2025
- IO Biotech Reports 2024 Business Highlights - March 5th, 2025
- FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis - March 5th, 2025
- Sandoz reports strong FY 2024 results and Q4 2024 sales - March 5th, 2025
- Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic... - March 5th, 2025
- Bavarian Nordic Publishes Annual Report 2024 - March 5th, 2025
- Orion and Aiforia extend collaboration to preclinical study evaluations - March 5th, 2025
- Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe - March 5th, 2025
- NewBiologix Announces White Paper on Improving the Manufacturing of Recombinant Adeno-Associated Viruses for Use in Cell & Gene Therapies - March 5th, 2025
- Initiation of share buyback program - March 5th, 2025
- Oculis to Present at Upcoming March Investor Conference - March 5th, 2025
- Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G) - March 3rd, 2025
- Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025 - March 3rd, 2025
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - March 3rd, 2025
- Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - March 3rd, 2025
- Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - March 3rd, 2025
- Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting - March 3rd, 2025
- Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call - March 3rd, 2025
- Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed... - March 3rd, 2025
- CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma - March 3rd, 2025
- Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration - March 3rd, 2025
- Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral... - March 3rd, 2025
- Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual... - March 3rd, 2025
- Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease... - March 3rd, 2025
- Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences - March 3rd, 2025
- Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies - March 3rd, 2025
- Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update - March 3rd, 2025
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - March 3rd, 2025
- AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - March 1st, 2025
- TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis - March 1st, 2025
- Ultimovacs ASA: Approval and publication of prospectus - March 1st, 2025
Recent Comments